Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Kura Oncology (KURA) Long-Term Debt Repayments (2018 - 2021)

Kura Oncology (KURA) reported Long-Term Debt Repayments of $6.5 million for Q2 2021, up 766.67% on a QoQ basis from $750000.0 in Q1 2021.

Kura Oncology (KURA) has 2 years of Long-Term Debt Repayments data on file, last reported at $6.5 million in Q2 2021.

  • Quarterly Long-Term Debt Repayments changed N/A year-over-year to $6.5 million in Q2 2021, while the trailing twelve-month figure through Dec 2021 was $7.2 million (changed N/A YoY) and the FY2021 annual result came in at $7.2 million, up 2800.0% from the prior year.
  • Long-Term Debt Repayments improved to $6.5 million in Q2 2021 per KURA's latest filing, from $750000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $6.5 million in Q2 2021 and bottomed at $250000.0 in Q4 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Kura Oncology 801.92 Mn 801.92 Mn 18.00 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2021 6.50 Mn
Jun 30, 2021 6.50 Mn
Mar 31, 2021 750,000.00
Mar 31, 2021 750,000.00
Dec 31, 2018 250,000.00
Dec 31, 2018 250,000.00
Sep 30, 2018 750,000.00
Sep 30, 2018 750,000.00